Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Kanavos · SciRah

Researcher profile · Semantic Scholar

P. Kanavos

Share profile

P. Kanavos — researcher profile on SciRah

h-index: 51
Works: 352
Citations: 9,136

Most-cited papers

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
O. Wouters, P. Kanavos, M. Mckee
2017Milbank Quarterly140 citations Open access
Semantic Scholar
Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art
M. Oliveira, Inês Mataloto, P. Kanavos
2019European Journal of Health Economics96 citations Open access
Semantic Scholar
Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
Anna-Maria Fontrier, E. Visintin, P. Kanavos
2021PharmacoEconomics - Open82 citations Open access
Semantic Scholar
Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients.
O. Efthymiadou, J. Mossman, P. Kanavos
2019Health Policy71 citations Open access
Semantic Scholar
Does external reference pricing deliver what it promises? Evidence on its impact at national level
P. Kanavos, Anna-Maria Fontrier, J. Gill, O. Efthymiadou
2019European Journal of Health Economics61 citations Open access
Semantic Scholar
Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America
A. Miracolo, Marisa K. Sophiea, M. Mills, P. Kanavos
2021Health Policy and Planning44 citations Open access
Semantic Scholar
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
D. Michaeli, M. Mills, P. Kanavos
2022Applied Health Economics and Health Policy42 citations Open access
Semantic Scholar
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
O. Wouters, Dale M. Sandberg, Anban W. Pillay, P. Kanavos
2019Social Science & Medicine (1967)41 citations Open access
Semantic Scholar
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
A. Angelis, M. Linch, G. Montibeller, T. Molina-López +5 more
2019Social Science & Medicine (1967)38 citations Open access
Semantic Scholar
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
D. Michaeli, M. Mills, T. Michaeli, A. Miracolo +1 more
2022Investigational new drugs34 citations Open access
Semantic Scholar
Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey.
J. Gill, Andrei Baiceanu, Paul John Clark, A. Langford +4 more
2018Future Oncology29 citations Open access
Semantic Scholar
A value framework to assess patient-facing digital health technologies that aim to improve chronic disease management: a Delphi approach.
M. Haig, C. Main, Danitza Chávez, P. Kanavos
2023Value in Health28 citations Open access
Semantic Scholar
An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
P. Kanavos, A. Angelis, M. Drummond
2019European Journal of Health Economics25 citations Open access
Semantic Scholar
A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
Entela Xoxi, F. Rumi, P. Kanavos, H. Dauben +4 more
2022Frontiers in Medical Technology23 citations Open access
Semantic Scholar
Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy
J. López-Bastida, J. Ramos-Goñi, I. Aranda-Reneo, D. Taruscio +2 more
2019Orphanet Journal of Rare Diseases22 citations Open access
Semantic Scholar
Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe.
M. Mills, P. Kanavos
2019Health Policy21 citations
Semantic Scholar
Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries
M. Mills, D. Michaeli, A. Miracolo, P. Kanavos
2023BMC Health Services Research20 citations Open access
Semantic Scholar
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
O. Efthymiadou, P. Kanavos
2022BMC Health Services Research20 citations Open access
Semantic Scholar
ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations.
A. Angelis, P. Kanavos, L. Phillips
2020Value in Health19 citations Open access
Semantic Scholar
International impact of external reference pricing: should national policy-makers care?
Anna-Maria Fontrier, J. Gill, P. Kanavos
2019European Journal of Health Economics18 citations Open access
Semantic Scholar
Variations in external reference pricing implementation: does it matter for public policy?
J. Gill, Anna-Maria Fontrier, D. Kyriopoulos, P. Kanavos
2019European Journal of Health Economics17 citations
Semantic Scholar
Using IMPrESS to guide policy change in multiple sclerosis
M. Tinelli, P. Kanavos, O. Efthymiadou, E. Visintin +2 more
2018Multiple Sclerosis17 citations Open access
Semantic Scholar
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study
A. Angelis, J. Mellerio, P. Kanavos
2022Orphanet Journal of Rare Diseases16 citations Open access
Semantic Scholar
Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?
J. López-Bastida, J. Ramos-Goñi, I. Aranda-Reneo, M. Trapero-Bertran +2 more
2019Health Policy16 citations
Semantic Scholar
Strategic procurement and international collaboration to improve access to medicines
A. Ferrario, T. Humbert, P. Kanavos, Hanne Bak Pedersen
2017Bulletin of the World Health Organization16 citations Open access
Semantic Scholar
Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration
B. Kamphuis, P. Kanavos
2021Health Policy OPEN15 citations Open access
Semantic Scholar
The Impact of External Reference Pricing within and across Countries
P. Kanavos, Anna-Maria Fontrier, J. Gill, O. Efthymiadou +1 more
201715 citations
Semantic Scholar
The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective.
E. Apostolou, Anna-Maria Fontrier, G. Efthimiadis, E. Kastritis +2 more
2023Hellenic Journal of Cardiology14 citations Open access
Semantic Scholar
Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.
T. Karlsen, S. Hutchinson, S. Zelber-Sagi, Patrizia Carrieri +44 more
2026The Lancet13 citations Open access
Semantic Scholar
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis.
P. Kanavos, E. Visintin, A. Angelis
2024The Lancet Oncology13 citations Open access
Semantic Scholar
Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis
A. Angelis, M. Thursz, V. Ratziu, A. O'Brien +6 more
2020Medical decision making13 citations Open access
Semantic Scholar
Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
M. Mills, P. Kanavos
2023PharmacoEconomics - Open12 citations Open access
Semantic Scholar
How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
M. Mills, P. Kanavos
2022Health Policy12 citations Open access
Semantic Scholar
Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
P. Kanavos, B. Kamphuis, Anna-Maria Fontrier, Georgia Colville Parkin +2 more
2020Health Policy12 citations Open access
Semantic Scholar
Access to Personalised Oncology in Europe
J. Gill, Anna-Maria Fontrier, A. Miracolo, P. Kanavos
202012 citations
Semantic Scholar
DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS
O. Efthymiadou, J. Mossman, P. Kanavos
2018International Journal of Technology Assessment in Health Care12 citations Open access
Semantic Scholar
Road traffic mortality and economic uncertainty: Evidence from the United States.
P. Kanavos, Sotiris Vandoros
2023Social Science & Medicine (1967)11 citations Open access
Semantic Scholar
Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
E. Visintin, M. Tinelli, P. Kanavos
2019Health Policy11 citations Open access
Semantic Scholar
FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
G. Candore, Claire Martin, M. J. Mills, Annabel Suter +9 more
2025Clinical pharmacology and therapy10 citations Open access
Semantic Scholar
Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries.
P. Kanavos, E. Visintin, Arianna Gentilini
2023Social Science & Medicine (1967)10 citations Open access
Semantic Scholar
Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries
O. Efthymiadou, P. Kanavos
2021International Journal of Technology Assessment in Health Care9 citations Open access
Semantic Scholar
How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe
Anna-Maria Fontrier, B. Kamphuis, P. Kanavos
2023European Journal of Health Economics8 citations Open access
Semantic Scholar
Do reimbursement recommendations by the Canadian Agency for Drugs and Technology in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario?
Anna-Maria Fontrier, P. Kanavos
2023Value in Health8 citations Open access
Semantic Scholar
Challenges for health systems seeking to embrace virtual health care for population health
P. Kanavos, M. Vogelsang, M. Haig, V. Kolovou
2022European Journal of Health Economics6 citations Open access
Semantic Scholar
From Vision to Reality: The EU’s Pharmaceutical Reforms and the Path to Improved Access
C. Main, Cathrin Schäfer, P. Kanavos
2025PharmacoEconomics - Open5 citations Open access
Semantic Scholar
A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development.
F. Augustovski, C. Colaci, M. Mills, Danitza Chávez +5 more
2024Value in Health5 citations Open access
Semantic Scholar
Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions
C. Main, M. Haig, Danitza Chávez, P. Kanavos
2023Medical decision making5 citations Open access
Semantic Scholar
PNS73 Payer Perspectives on Pricing of MULTI-Indication Products
M. Mills, A. Miracolo, D. Michaeli, P. Kanavos
20204 citations Open access
Semantic Scholar
A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia—results from a multi-stakeholder workshop
H. Al-Omar, A. Almuhsin, L. Almudaiyan, Amal H. Al-Najjar +11 more
2025Journal of Medical Economics3 citations Open access
Semantic Scholar
A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom.
A. Angelis, G. Montibeller, P. Kanavos
2023Social Science & Medicine (1967)3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Anna-Maria Fontrier×10
Invite
Anna-Maria Fontrier — researcher profile on SciRah
M. Mills×9
Invite
M. Mills — researcher profile on SciRah
O. Efthymiadou×7
Invite
O. Efthymiadou — researcher profile on SciRah
A. Angelis×7
Invite
A. Angelis — researcher profile on SciRah

×6

Invite

J. Gill — researcher profile on SciRah

Invite

E. Visintin — researcher profile on SciRah

Invite

A. Miracolo — researcher profile on SciRah

Invite

J. Mossman — researcher profile on SciRah

Invite

D. Michaeli — researcher profile on SciRah

Invite

M. Haig — researcher profile on SciRah

Invite

C. Main — researcher profile on SciRah

Danitza Chávez×3

Invite

Danitza Chávez — researcher profile on SciRah